Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2021
Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell TherapyMingming Zhang, Linghui Zhou, Houli Zhao, et al.
Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences|May 12, 2020
[Management of COVID-19: the Zhejiang experience]Kaijin Xu, Hongliu Cai, Yihong Shen, et al.
Infectious Microbes & Diseases|June 6, 2025
Translation: Management of Coronavirus Disease 2019 (COVID-19): Experience in Zhejiang Province, ChinaKaijin Xu, Hongliu Cai, Yihong Shen, et al.
Bone Marrow Transplantation|August 20, 2025
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphomaYetian Dong, Tingting Yang, Mengyu Zhao, et al.
Cell Transplantation|January 25, 2024
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients With Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic FactorsBingqian Jiang, Yanmin Zhao, Yi Luo, et al.
Annals of Hematology|June 3, 2026
Integrating genomic features for prognosis in Chinese patients with diffuse large B-cell lymphoma following R-CHOP therapyShi Han, Linghui Zhou, Haiqiong Zheng, et al.
Plos One|June 12, 2014
The choice of regimens based on bortezomib for patients with newly diagnosed multiple myelomaJingsong He, Li Yang, Xiaoyan Han, et al.
The Lancet. Haematology|February 1, 2023
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trialMingming Zhang, Guoqing Wei, Linghui Zhou, et al.
Biomarker Research|July 7, 2021
Inflammation-related genes S100s, RNASE3, and CYBB and risk of leukemic transformation in patients with myelodysplastic syndrome with myelofibrosisMinghua Hong, Junqing Wu, Lifeng Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2021
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaYongxian Hu, Yali Zhou, Mingming Zhang, et al.
Pageof 18